Relay Therapeutics (RLAY) Accumulated Depreciation & Amortization (2020 - 2025)
Relay Therapeutics (RLAY) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $21.5 million as the latest value for Q4 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization fell 25.47% to $21.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.5 million, a 25.47% decrease, with the full-year FY2025 number at $21.5 million, down 25.47% from a year prior.
- Accumulated Depreciation & Amortization was $21.5 million for Q4 2025 at Relay Therapeutics, down from $28.9 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $28.9 million in Q4 2024 to a low of $14.4 million in Q4 2021.
- A 5-year average of $21.4 million and a median of $21.5 million in 2025 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: soared 36.44% in 2021, then decreased 25.47% in 2025.
- Relay Therapeutics' Accumulated Depreciation & Amortization stood at $14.4 million in 2021, then rose by 27.99% to $18.4 million in 2022, then increased by 28.24% to $23.6 million in 2023, then grew by 22.6% to $28.9 million in 2024, then fell by 25.47% to $21.5 million in 2025.
- Per Business Quant, the three most recent readings for RLAY's Accumulated Depreciation & Amortization are $21.5 million (Q4 2025), $28.9 million (Q4 2024), and $23.6 million (Q4 2023).